Last updated: May 26, 2026
Ertugliflozin and sitagliptin phosphate supply is concentrated around a small set of high-volume API producers, with additional specialty capacity for intermediates and finished-dose manufacturing. In practice, procurement splits into (1) APIs and key intermediates, (2) finished dosage forms and packaging, and (3) validated contract manufacturing for launch and lifecycle extensions.
The supplier landscape depends on whether the product is sold as a standalone (ERTUGLIFLOZIN or SITAGLIPTIN PHOSPHATE) or as combination therapy. For supply planning, the critical procurement objects are: the API (ertugliflozin, sitagliptin phosphate), the stereochemically and impurity-controlled intermediates used in their synthetic routes, and the regulated finished-dose manufacturers that hold US FDA inspection readiness for tablets.
What companies supply ertugliflozin API and key intermediates?
Ertugliflozin API supply is typically provided by global generic and specialty pharma API manufacturers with DMF/CEP-backed dossiers for US and EU distribution. Procurement focus is on:
- API manufacturer holding the primary regulatory filings for ertugliflozin.
- Intermediate suppliers controlling the chiral steps and impurity profile.
- Toll manufacturers performing GMP synthesis of late-stage intermediates.
Which supplier archetypes dominate ertugliflozin?
- US-facing API manufacturers with established DMF programs for diabetes SGLT2 inhibitor chemistry.
- Indian and Chinese API producers that supply international finished-dose firms, often via intermediates and bulk drug substance.
- Specialty chemical houses supplying critical building blocks, then transferring into GMP intermediate steps under contract.
How to map ertugliflozin supply chain by procurement object
- API (ertugliflozin): bulk drug substance supplied to finished-dose packers and CDMOs.
- Key intermediates: controlled intermediates used for final API crystallization and impurity management.
- Process validation readiness: suppliers with documented batch history and regulatory inspection track record.
What companies supply sitagliptin phosphate API and key intermediates?
Sitagliptin phosphate is a high-volume DPP-4 inhibitor, which supports a broader supplier base for API and intermediates than many newer diabetes actives. Procurement focus is on:
- Sitagliptin base vs phosphate salt control: salt form impacts stability and tablet performance.
- Impurity management: sitagliptin impurity profile is tightly controlled in validated manufacturing.
- Consistent solid-state properties: polymorph/crystal habit controls downstream filtration and tableting performance.
Which supplier archetypes dominate sitagliptin phosphate?
- Large-scale API makers with mature commercialization history for sitagliptin.
- Intermediate manufacturers that supply de-risked upstream steps (building blocks and salt formation-ready intermediates).
- Finished-dose CDMOs producing tablets for multiple brand and generic customers under GMP and regulatory compliance.
What finished-dose manufacturers make ertugliflozin and sitagliptin phosphate tablets?
Finished-dose supply is split between:
- Brand manufacturing sites for originator products (when applicable).
- Generic and combination tablet manufacturers producing therapeutically equivalent tablets for US and export markets.
- CDMOs performing direct compression and film coating, then packaging and release.
What matters for tablet supply procurement
- Tablet press capability for film coating and uniformity by content.
- Stability for long-term storage, especially for combination products.
- Ability to run validated dissolution specs for SGLT2 inhibitor and DPP-4 inhibitor blends.
How do suppliers differ for combination products vs standalone drugs?
If ertugliflozin and sitagliptin are supplied in a combination format, procurement shifts from only API sourcing to also:
- Co-formulation feasibility and compatibility.
- Bridging dissolution work for new tablet strengths.
- Line clearance and contamination controls because these actives are potent and typically manufactured on dedicated campaigns.
What does combination manufacturing change
- More constraints around blend uniformity and stability for two-actives-plus-excipient systems.
- Higher importance of co-packing and packaging validation to prevent mix-ups across strengths.
Which API manufacturers are most likely to be in the active supplier set for these diabetes drugs?
In practical procurement workflows, the “most likely active supplier set” is identified by:
- Whether the firm has a working DMF/US regulatory history for the API or key intermediate.
- Whether the firm has existing supply contracts with major generic and branded finished-dose manufacturers.
- Whether the firm has recent inspection history acceptable to customers.
For many pharmaceutical buyers, long-term supply relationships are consolidated with suppliers that:
- supply both API and key intermediates,
- support fast change control and scale-up,
- can execute right-first-time batches for regulatory releases.
What are the typical manufacturing and regulatory barriers that affect supplier qualification?
DMF, CEP, and inspection readiness
- US buyers prefer API suppliers with DMF access pathways and a documented inspection track record.
- EU buyers often require CEP-backed quality.
Impurity control and batch consistency
- Both APIs are impurity sensitive.
- Qualification requires impurity spec adherence at scale and reproducible crystallization.
Solid-state form and salt control
- Sitagliptin phosphate salt form requires controlled formation and verification.
- Supplier solid-state characterization reduces risk of bioavailability and dissolution drift.
What generic entry risks exist for products containing ertugliflozin or sitagliptin phosphate (supply-side view)?
Supply-side generic risks usually come from:
- API bottlenecks when one supplier dominates a given impurity-controlled intermediate.
- Change control delays (new catalysts, solvent swaps, crystallization changes).
- Regulatory friction if late-stage impurity drift forces retesting or batch rejection.
From a buyer perspective, these risks are managed by:
- dual sourcing the API and key intermediates,
- pre-qualifying an alternate supply chain,
- locking validated specs for solid-state form and dissolution.
Key takeaways
- Ertugliflozin and sitagliptin phosphate supply is anchored by a concentrated group of GMP API manufacturers plus intermediate suppliers that control critical steps and impurity profiles.
- Procurement should be structured around regulatory-ready deliverables: API (active and correct salt form where applicable), key intermediates, and finished-dose manufacturing capability for tablets and combination formats.
- Combination manufacturing increases technical and validation constraints, so supplier qualification should include compatibility and dissolution/stability readiness for the specific strength and tablet design.
FAQs
Who are the main ertugliflozin API suppliers for US manufacturers?
The main suppliers are typically those with US DMF-based regulatory submissions and demonstrated inspection history for SGLT2 inhibitor APIs.
Who supplies sitagliptin phosphate for generic tablet makers?
Suppliers are usually large-scale API manufacturers with validated solid-state control for sitagliptin phosphate salt formation and impurity profiling.
Can the same supplier make both ertugliflozin and sitagliptin phosphate?
Some firms cover both actives, but most buyers still dual-source to reduce bottlenecks tied to chiral steps (ertugliflozin) and salt/solid-state control (sitagliptin phosphate).
What intermediate is most likely to constrain ertugliflozin supply?
The most constrained step is typically the chiral or late-stage intermediate with the tightest impurity controls and highest sensitivity to scale-up.
What is the biggest qualification issue when switching sitagliptin phosphate API suppliers?
Salt form and solid-state properties, plus impurity comparability and dissolution performance, usually drive most qualification friction.
References (APA)
- No sources were provided in the prompt to support a verified list of specific companies and supplier names.
